Fosifloxuridine nafalbenamide
- Generic Name
- Fosifloxuridine nafalbenamide
- Drug Type
- Small Molecule
- Chemical Formula
- C29H29FN3O9P
- CAS Number
- 1332837-31-6
- Unique Ingredient Identifier
- 4YO6QT3SZ9
- Background
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Conditions
- Advanced CancerAdvanced Solid TumorNeoplasm MalignantMetastatic CancerMelanomaClassical Hodgkin LymphomaNon Small Cell Lung CancerRenal Cell CarcinomaUrothelial CarcinomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 91
- Registration Number
- NCT05714553
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer MetastaticNeoplasm, ColorectalColorectal AdenocarcinomaColorectal CancerColorectal Neoplasms
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 182
- Registration Number
- NCT05678257
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
- Conditions
- Neoplasms, ColorectalColorectal CarcinomaColorectal NeoplasmsColorectal TumorsColorectal Cancer
- Interventions
- Drug: NUFIRIDrug: NUFOX + VEGF pathway inhibitorDrug: NUFOXDrug: NUFIRI + VEGF pathway inhibitorDrug: NUFIRI + EGFR inhibitorDrug: NUC-3373 + bevacizumabDrug: NUFOX + EGFR inhibitor
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 111
- Registration Number
- NCT03428958
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Seattle Cancer Center, Seattle, Washington, United States
NUC-3373 in Advanced Solid Tumours
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 62
- Registration Number
- NCT02723240
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧Oxford University Hospitals NHS Trust, Oxford, United Kingdom
🇬🇧Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.